Fluoroquinolones are a class of antibiotics frequently and globally prescribed as a measure to cure bacterial infections in humans and animals. There is an extensive list of drugs in this class in multiple forms, but the most familiar in the United States are the generic oral forms such as ciprofloxacin, levofloxacin, moxifloxacin and the name brand Cipro. 

Both U.S. and European regulators have only strengthened fluoroquinolone safety warnings over the last decade. The Food & Drug Administration (FDA) black boxed warnings state that systemic fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that can occur together, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and the worsening of myasthenia gravis. FDA warnings and labeling also address psychiatric and neurologic effects, serious blood sugar disturbances including hypoglycemia, increased risk of aortic aneurysm or dissection in certain patients, and ciprofloxacin’s inhibition of CYP1A2.  The European Medicines Agency (EMA) has issued even broader language, warning that fluoroquinolones can be associated with prolonged, disabling, and potentially irreversible serious adverse reactions affecting several, sometimes multiple, systems, organ classes, and senses. EMA examples include musculoskeletal, nervous system, psychiatric, and sensory effects, such as tendon problems, joint or limb pain, gait disturbance, neuropathy, depression, fatigue, memory impairment, sleep disorders, and impaired hearing, vision, taste, or smell.  

Most people are unaware that fluoroquinolones can be used in surgical procedures via IV and given for prophylactic measures. In addition, fluoroquinolone residues have been documented in environmental and agricultural settings, including wastewater, surface waters, sediments, soils, manure-amended fields, livestock and poultry production environments, and some animal-derived foods.  Governments, the global public, and medical communities remain largely uninformed about a growing worldwide silent epidemic of individuals experiencing extensive adverse drug reactions, often alongside multiple medical complications, that are frequently misdiagnosed, dismissed, or never properly diagnosed.

In recent years, scientific evidence has grown showing that fluoroquinolones may interfere with mitochondria, the energy-producing structures inside cells. While direct published research in affected patients is still urgently needed, laboratory findings suggest that ciprofloxacin and levofloxacin can disrupt mitochondrial function in more than one way. Ciprofloxacin may interfere with how mitochondria copy and maintain their own DNA, while both ciprofloxacin and levofloxacin may affect mitochondrial proteins involved in energy production and stress responses. Because mitochondria help power nerves, muscles, the brain, and nearly every system in the body, these findings help support a biologically plausible explanation for mitochondrial stress, impaired cell function, and disrupted energy production after fluoroquinolone exposure. Since mitochondrial dysfunction is increasingly linked to many chronic and degenerative diseases, these changes may represent an early biological warning sign, or prelude, to more serious disease processes over time. 

In 2023, over 14 million fluoroquinolone prescriptions were dispensed in the U.S., despite FDA warnings about disabling and potentially permanent side effects.   The true population rate of persistent multisystem injury remains uncertain, especially taking into consideration of repeated use, IV dosing, or underlying genetic vulnerabilities that may impair drug detoxification or cellular repair.  Less than 1% of adverse reactions are officially reported, and due to the prescribing frequency of these medications, hundreds of thousands of Americans could be living with fluoroquinolone toxicity, most without recognition or support.  Tragically, millions more can be affected worldwide.